

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Ceftolozane / Tazobactam Injection Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
120 Moorgate  
EC2M 6UR London, United Kingdom

Telephone : +44 (0) 2081548000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

|                                                                |                                                                                  |
|----------------------------------------------------------------|----------------------------------------------------------------------------------|
| Respiratory sensitisation, Category 1                          | H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| Specific target organ toxicity - repeated exposure, Category 2 | H373: May cause damage to organs through prolonged or repeated exposure.         |
| Short-term (acute) aquatic hazard, Category 1                  | H400: Very toxic to aquatic life.                                                |
| Long-term (chronic) aquatic hazard, Category 1                 | H410: Very toxic to aquatic life with long lasting effects.                      |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

### 2.2 Label elements

**Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

Hazard pictograms : 

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H373 May cause damage to organs through prolonged or repeated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
P284 Wear respiratory protection.  
**Response:**  
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

Hazardous components which must be listed on the label:

Ceftolozane  
Tazobactam

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

| Chemical name | CAS-No.<br>EC-No.<br>Index-No. | Classification | Concentration<br>(% w/w) |
|---------------|--------------------------------|----------------|--------------------------|
|---------------|--------------------------------|----------------|--------------------------|

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

|             | Registration number |                                                                                                                                                                                                                |                  |
|-------------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Ceftolozane | 689293-68-3         | Resp. Sens. 1B;<br>H334<br>STOT RE 2; H373<br>(Kidney)<br>Aquatic Acute 1;<br>H400<br>Aquatic Chronic 1;<br>H410<br><br>M-Factor (Acute<br>aquatic toxicity): 10<br>M-Factor (Chronic<br>aquatic toxicity): 10 | $\geq 30 - < 50$ |
| Tazobactam  | 89786-04-9          | Resp. Sens. 1B;<br>H334<br>STOT RE 2; H373<br>(Liver)<br>Aquatic Acute 1;<br>H400<br>Aquatic Chronic 2;<br>H411<br><br>M-Factor (Acute<br>aquatic toxicity): 1                                                 | $\geq 10 - < 20$ |

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- |                            |   |                                                                                                                                                                             |
|----------------------------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| General advice             | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.                      |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>If not breathing, give artificial respiration.<br>If breathing is difficult, give oxygen.<br>Get medical attention.                     |
| In case of skin contact    | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Get medical attention if symptoms occur.                                                       |
| In case of eye contact     | : | If in eyes, rinse well with water.                                                                                                                                          |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).  
Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
May cause damage to organs through prolonged or repeated exposure.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides  
Chlorine compounds  
Nitrogen oxides (NO<sub>x</sub>)

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.  
Add excess liquid to allow the material to enter into solution.  
Soak up with inert absorbent material.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

|                         |   |                                                                                                                                                                                                                                                                              |
|-------------------------|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Local/Total ventilation | : | causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.                                                                                                                                                       |
| Advice on safe handling | : | Use only with adequate ventilation.                                                                                                                                                                                                                                          |
|                         | : | Do not breathe dust.                                                                                                                                                                                                                                                         |
|                         | : | Do not swallow.                                                                                                                                                                                                                                                              |
|                         | : | Avoid contact with eyes.                                                                                                                                                                                                                                                     |
|                         | : | Avoid prolonged or repeated contact with skin.                                                                                                                                                                                                                               |
|                         | : | Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment                                                                                                                                             |
|                         | : | Keep container tightly closed.                                                                                                                                                                                                                                               |
|                         | : | Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.                                                            |
|                         | : | Minimize dust generation and accumulation.                                                                                                                                                                                                                                   |
|                         | : | Keep container closed when not in use.                                                                                                                                                                                                                                       |
|                         | : | Keep away from heat and sources of ignition.                                                                                                                                                                                                                                 |
|                         | : | Take precautionary measures against static discharges.                                                                                                                                                                                                                       |
|                         | : | Take care to prevent spills, waste and minimize release to the environment.                                                                                                                                                                                                  |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.                                                           |
|                         | : | The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

### 7.2 Conditions for safe storage, including any incompatibilities

|                                               |   |                                                                                                                             |
|-----------------------------------------------|---|-----------------------------------------------------------------------------------------------------------------------------|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Keep tightly closed.<br>Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents                                                   |

### 7.3 Specific end use(s)

|                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

|                  |                                                |
|------------------|------------------------------------------------|
| dust of any kind | 10 mg/m <sup>3</sup>                           |
|                  | Value type (Form of exposure): TWA (Inhalable) |
|                  | Basis: GB EH40                                 |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

Version 5.2      Revision Date: 14.04.2025      SDS Number: 9825113-00010      Date of last issue: 28.09.2024  
Date of first issue: 12.10.2021

4 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (Respirable fraction)  
Basis: GB EH40

| Components  | CAS-No.                         | Value type (Form of exposure) | Control parameters             | Basis    |
|-------------|---------------------------------|-------------------------------|--------------------------------|----------|
| Ceftolozane | 689293-68-3                     | TWA                           | 1000 µg/m <sup>3</sup> (OEB 1) | Internal |
|             | Further information: DSEN, RSEN |                               |                                |          |
|             |                                 | Wipe limit                    | 100 µg/100 cm <sup>2</sup>     | Internal |
| Tazobactam  | 89786-04-9                      | TWA                           | 250 µg/m <sup>3</sup> (OEB 2)  | Internal |
|             | Further information: RSEN       |                               |                                |          |
|             |                                 | Wipe limit                    | 100 µg/100 cm <sup>2</sup>     | Internal |

### Derived No Effect Level (DNEL)

| Substance name           | End Use   | Exposure routes | Potential health effects   | Value                     |
|--------------------------|-----------|-----------------|----------------------------|---------------------------|
| Sodium chloride          | Workers   | Inhalation      | Long-term systemic effects | 2068.62 mg/m <sup>3</sup> |
|                          | Workers   | Inhalation      | Acute systemic effects     | 2068.62 mg/m <sup>3</sup> |
|                          | Workers   | Skin contact    | Long-term systemic effects | 295.52 mg/kg bw/day       |
|                          | Workers   | Skin contact    | Acute systemic effects     | 295.52 mg/kg bw/day       |
|                          | Consumers | Inhalation      | Long-term systemic effects | 443.28 mg/m <sup>3</sup>  |
|                          | Consumers | Inhalation      | Acute systemic effects     | 443.28 mg/m <sup>3</sup>  |
|                          | Consumers | Skin contact    | Long-term systemic effects | 126.65 mg/kg bw/day       |
|                          | Consumers | Skin contact    | Acute systemic effects     | 126.65 mg/kg bw/day       |
|                          | Consumers | Ingestion       | Long-term systemic effects | 126.65 mg/kg bw/day       |
|                          | Consumers | Ingestion       | Acute systemic effects     | 126.65 mg/kg bw/day       |
| L-Arginine hydrochloride | Workers   | Inhalation      | Long-term systemic effects | 668.2 mg/m <sup>3</sup>   |
|                          | Workers   | Skin contact    | Long-term systemic effects | 947.5 mg/kg bw/day        |
|                          | Consumers | Inhalation      | Long-term systemic effects | 164.8 mg/m <sup>3</sup>   |
|                          | Consumers | Skin contact    | Long-term systemic effects | 473.8 mg/kg bw/day        |
|                          | Consumers | Ingestion       | Long-term systemic effects | 47.8 mg/kg bw/day         |

### Predicted No Effect Concentration (PNEC)

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

| Substance name           | Environmental Compartment | Value                        |
|--------------------------|---------------------------|------------------------------|
| Sodium chloride          | Fresh water               | 5 mg/l                       |
|                          | Sewage treatment plant    | 500 mg/l                     |
|                          | Soil                      | 4.86 mg/kg dry weight (d.w.) |
| L-Arginine hydrochloride | Fresh water               | 2.2 mg/l                     |
|                          | Marine water              | 0.22 mg/l                    |
|                          | Intermittent use/release  | 22 mg/l                      |
|                          | Sewage treatment plant    | 12000 mg/l                   |
|                          | Fresh water sediment      | 4.437 mg/kg                  |
|                          | Marine sediment           | 0.444 mg/kg                  |

### 8.2 Exposure controls

#### Engineering measures

Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

|                          |   |                                                                                                                                                                                                                                                                                                                |
|--------------------------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Eye/face protection      | : | Wear safety glasses with side shields or goggles.<br>If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.<br>Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Hand protection          | : |                                                                                                                                                                                                                                                                                                                |
| Material                 | : | Chemical-resistant gloves                                                                                                                                                                                                                                                                                      |
| Skin and body protection | : | Work uniform or laboratory coat.                                                                                                                                                                                                                                                                               |
| Respiratory protection   | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.<br>Equipment should conform to BS EN 143                                                                                                  |
| Filter type              | : | Particulates type (P)                                                                                                                                                                                                                                                                                          |

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

|                                         |   |                   |
|-----------------------------------------|---|-------------------|
| Appearance                              | : | powder            |
| Colour                                  | : | No data available |
| Odour                                   | : | No data available |
| Odour Threshold                         | : | No data available |
| pH                                      | : | No data available |
| Melting point/freezing point            | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point                             | : | Not applicable    |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

|                                                  |   |                                                                                 |
|--------------------------------------------------|---|---------------------------------------------------------------------------------|
| Evaporation rate                                 | : | No data available                                                               |
| Flammability (solid, gas)                        | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : | No data available                                                               |
| Upper explosion limit / Upper flammability limit | : | No data available                                                               |
| Lower explosion limit / Lower flammability limit | : | No data available                                                               |
| Vapour pressure                                  | : | No data available                                                               |
| Relative vapour density                          | : | No data available                                                               |
| Relative density                                 | : | No data available                                                               |
| Density                                          | : | No data available                                                               |
| Solubility(ies)                                  |   |                                                                                 |
| Water solubility                                 | : | No data available                                                               |
| Partition coefficient: n-octanol/water           | : | No data available                                                               |
| Auto-ignition temperature                        | : | No data available                                                               |
| Decomposition temperature                        | : | No data available                                                               |
| Viscosity                                        |   |                                                                                 |
| Viscosity, kinematic                             | : | No data available                                                               |
| Explosive properties                             | : | Not explosive                                                                   |
| Oxidizing properties                             | : | The substance or mixture is not classified as oxidizing.                        |

### 9.2 Other information

|                  |   |                   |
|------------------|---|-------------------|
| Molecular weight | : | No data available |
| Particle size    | : | No data available |

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Ceftolozane:

Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg  
Application Route: Intravenous

LD50 (Mouse): > 1,500 mg/kg  
Application Route: Intravenous

LD50 (Dog): > 2,000 mg/kg  
Application Route: Intravenous

##### Tazobactam:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 5,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): > 5,000 mg/kg  
Application Route: Intravenous

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

LD50 (Mouse): > 5,000 mg/kg  
Application Route: Intravenous

LD50 (Dog): > 5,000 mg/kg  
Application Route: Intravenous

### Skin corrosion/irritation

Not classified based on available information.

### Serious eye damage/eye irritation

Not classified based on available information.

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

### Components:

#### Ceftolozane:

|           |                     |
|-----------|---------------------|
| Test Type | : Maximisation Test |
| Species   | : Guinea pig        |
| Result    | : Sensitiser        |

#### Tazobactam:

|        |              |
|--------|--------------|
| Result | : Sensitiser |
|--------|--------------|

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Ceftolozane:

|                       |                                                                          |
|-----------------------|--------------------------------------------------------------------------|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative |
|-----------------------|--------------------------------------------------------------------------|

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: positive

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

|                      |                                                                                                       |
|----------------------|-------------------------------------------------------------------------------------------------------|
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo<br>cytogenetic assay)<br>Species: Mouse |
|----------------------|-------------------------------------------------------------------------------------------------------|

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with  
mammalian liver cells in vivo

Species: Mouse

Result: negative

### Tazobactam:

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: positive

Test Type: Chromosome aberration test in vitro

Test system: Chinese hamster fibroblasts

Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with  
mammalian liver cells in vivo

Species: Mouse

Result: negative

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Ceftolozane:

Effects on fertility

: Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intravenous injection  
Fertility: NOAEL: 1,000 mg/kg body weight  
Result: No effects on fertility

Effects on foetal develop-  
ment

: Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 2,000 mg/kg body weight  
Remarks: No significant adverse effects were reported

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Remarks: No significant adverse effects were reported

### Tazobactam:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intraperitoneal injection  
Fertility: NOAEL: 640 mg/kg body weight

Effects on foetal develop- : Test Type: Embryo-foetal development  
ment Species: Rat  
Application Route: Intraperitoneal injection  
Developmental Toxicity: NOAEL: 40 mg/kg body weight  
Result: Effects on early embryonic development

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight  
Result: No effects on foetal development

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Ceftolozane:

Target Organs : Kidney  
Assessment : May cause damage to organs through prolonged or repeated exposure.

#### Tazobactam:

Target Organs : Liver  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Ceftolozane:

Species : Rat  
NOAEL : 1,000 mg/kg  
Application Route : Intravenous

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Exposure time : 28 days  
Target Organs : Kidney  
Symptoms : No adverse effects

Species : Dog  
LOAEL : 300 mg/kg  
Exposure time : 28 days  
Target Organs : Kidney

### Tazobactam:

Species : Rat  
NOAEL : 40 mg/kg  
Application Route : Intraperitoneal  
Exposure time : 6 Months  
Target Organs : Liver

Species : Dog  
NOAEL : 40 mg/kg  
LOAEL : 80 mg/kg  
Application Route : Intraperitoneal  
Exposure time : 6 Months  
Target Organs : Liver

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Ceftolozane:

Ingestion : Symptoms: Diarrhoea, Fever, Headache, Nausea, Skin irritation, Gastrointestinal discomfort

#### Tazobactam:

Inhalation : Remarks: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

#### Ceftolozane:

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae): 0.0401 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.0018 mg/l  
Exposure time: 72 h

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- : 10  
icity)

Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC : 560 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox- : NOEC: 10 mg/l  
icity) Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other : NOEC: 9.6 mg/l  
aquatic invertebrates (Chron- Exposure time: 21 d  
ic toxicity) Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic : 10  
toxicity)

### **Tazobactam:**

Toxicity to algae/aquatic : EC50 (Anabaena flos-aquae): 0.96 mg/l  
plants Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.44 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- : 1  
icity)

Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC : 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox- : NOEC: 10.6 mg/l  
icity) Exposure time: 32 d

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other : NOEC: 9.6 mg/l  
aquatic invertebrates (Chron- Exposure time: 21 d  
ic toxicity) Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

### 12.2 Persistence and degradability

#### Components:

##### **Ceftolozane:**

Biodegradability : Result: Not readily biodegradable.  
Method: OECD Test Guideline 301D

##### **Tazobactam:**

Biodegradability : Result: Not readily biodegradable.  
Method: OECD Test Guideline 301D

### 12.3 Bioaccumulative potential

#### Components:

##### **Ceftolozane:**

Partition coefficient: n- : log Pow: -0.21  
octanol/water

##### **Tazobactam:**

Partition coefficient: n- : log Pow: -0.63  
octanol/water

### 12.4 Mobility in soil

#### Components:

##### **Ceftolozane:**

Distribution among environ- : log Koc: 3.3  
mental compartments Method: OECD Test Guideline 106

##### **Tazobactam:**

Distribution among environ- : log Koc: 0.87  
mental compartments

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered  
to be either persistent, bioaccumulative and toxic (PBT), or  
very persistent and very bioaccumulative (vPvB) at levels of  
0.1% or higher.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : This substance/mixture does not contain components considered to have endocrine disrupting properties for environment according to UK REACH Article 57(f).

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

|                        |                                                                                                                                                                                                                                                                                                                      |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Product                | : Dispose of in accordance with local regulations.<br>According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.<br>Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.<br>Do not dispose of waste into sewer. |
| Contaminated packaging | : Empty containers should be taken to an approved waste handling site for recycling or disposal.<br>If not otherwise specified: Dispose of as unused product.                                                                                                                                                        |

## SECTION 14: Transport information

### 14.1 UN number

|      |           |
|------|-----------|
| ADN  | : UN 3077 |
| ADR  | : UN 3077 |
| RID  | : UN 3077 |
| IMDG | : UN 3077 |
| IATA | : UN 3077 |

### 14.2 UN proper shipping name

|      |                                                                                   |
|------|-----------------------------------------------------------------------------------|
| ADN  | : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(Ceftolozane, Tazobactam) |
| ADR  | : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(Ceftolozane, Tazobactam) |
| RID  | : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(Ceftolozane, Tazobactam) |
| IMDG | : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(Ceftolozane, Tazobactam) |
| IATA | : Environmentally hazardous substance, solid, n.o.s.                              |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

(Ceftolozane, Tazobactam)

### 14.3 Transport hazard class(es)

|             | Class | Subsidiary risks |
|-------------|-------|------------------|
| <b>ADN</b>  | : 9   |                  |
| <b>ADR</b>  | : 9   |                  |
| <b>RID</b>  | : 9   |                  |
| <b>IMDG</b> | : 9   |                  |
| <b>IATA</b> | : 9   |                  |

### 14.4 Packing group

|                                          |                 |
|------------------------------------------|-----------------|
| <b>ADN</b>                               |                 |
| Packing group                            | : III           |
| Classification Code                      | : M7            |
| Hazard Identification Number             | : 90            |
| Labels                                   | : 9             |
| <b>ADR</b>                               |                 |
| Packing group                            | : III           |
| Classification Code                      | : M7            |
| Hazard Identification Number             | : 90            |
| Labels                                   | : 9             |
| Tunnel restriction code                  | : (-)           |
| <b>RID</b>                               |                 |
| Packing group                            | : III           |
| Classification Code                      | : M7            |
| Hazard Identification Number             | : 90            |
| Labels                                   | : 9             |
| <b>IMDG</b>                              |                 |
| Packing group                            | : III           |
| Labels                                   | : 9             |
| EmS Code                                 | : F-A, S-F      |
| <b>IATA (Cargo)</b>                      |                 |
| Packing instruction (cargo aircraft)     | : 956           |
| Packing instruction (LQ)                 | : Y956          |
| Packing group                            | : III           |
| Labels                                   | : Miscellaneous |
| <b>IATA (Passenger)</b>                  |                 |
| Packing instruction (passenger aircraft) | : 956           |
| Packing instruction (LQ)                 | : Y956          |
| Packing group                            | : III           |
| Labels                                   | : Miscellaneous |

### 14.5 Environmental hazards

**ADN**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

Environmentally hazardous : yes

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Not applicable

UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation : Not applicable

The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain) : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

UK REACH List of substances subject to authorisation (Annex XIV) : Not applicable

GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation : Not applicable

Control of Major Accident Hazards Regulations 2015 (COMAH)

|    |                          |                     |                     |
|----|--------------------------|---------------------|---------------------|
| E1 | ENVIRONMENTAL<br>HAZARDS | Quantity 1<br>100 t | Quantity 2<br>200 t |
|----|--------------------------|---------------------|---------------------|

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

94/33/EC on the protection of young people at work.

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

#### Full text of H-Statements

H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H373 : May cause damage to organs through prolonged or repeated exposure.  
H400 : Very toxic to aquatic life.  
H410 : Very toxic to aquatic life with long lasting effects.  
H411 : Toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Aquatic Acute : Short-term (acute) aquatic hazard  
Aquatic Chronic : Long-term (chronic) aquatic hazard  
Resp. Sens. : Respiratory sensitisation  
STOT RE : Specific target organ toxicity - repeated exposure  
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits  
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization;

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Ceftolozane / Tazobactam Injection Formula- tion

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 28.09.2024  |
| 5.2     | 14.04.2025     | 9825113-00010 | Date of first issue: 12.10.2021 |

KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

|                   |      |
|-------------------|------|
| Resp. Sens. 1     | H334 |
| STOT RE 2         | H373 |
| Aquatic Acute 1   | H400 |
| Aquatic Chronic 1 | H410 |

### Classification procedure:

|                    |
|--------------------|
| Calculation method |
| Calculation method |
| Calculation method |
| Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN